CAJ | 학술논문

目的评价吉非替尼一线治疗晚期非小细胞肺癌(NSCLC)的疗效及不良反应.方法 58例晚期NSCLC患者接受吉非替尼250mg/d治疗,连续用药至疾病进展或出现严重的不良反应.治疗2个月后进行疗效和不良反应分析.河南省安阳市肿瘤医院放疗三科同时对58例患者的肿瘤标本进行表皮生长因子受体(EGFR)基因状态检测.结果 58例患者中完全缓解2例(3.4％),部分缓解16例(27.6％),疾病稳定24例(41.4％),疾病进展16例(36.5％),疾病控制率为72.4％.单因素分析结果显示临床获益和性别、组织学类型、吸烟史、EGFR突变状态显著相关(P＜0.05),而与临床分期无关.58例标本中30例EGFR为突变型.EGFR的突变率为51.7％.结论吉非替尼一线治疗NSCLC疗效较好,耐受性良好,可明显改善症状,提高患者生活质量.
목적 평개길비체니일선치료만기비소세포폐암(NSCLC)적료효급불량반응.방법 58례만기NSCLC환자접수길비체니250mg/d치료,련속용약지질병진전혹출현엄중적불량반응.치료2개월후진행료효화불량반응분석.하남성안양시종류의원방료삼과동시대58례환자적종류표본진행표피생장인자수체(EGFR)기인상태검측.결과 58례환자중완전완해2례(3.4％),부분완해16례(27.6％),질병은정24례(41.4％),질병진전16례(36.5％),질병공제솔위72.4％.단인소분석결과현시림상획익화성별、조직학류형、흡연사、EGFR돌변상태현저상관(P＜0.05),이여림상분기무관.58례표본중30례EGFR위돌변형.EGFR적돌변솔위51.7％.결론 길비체니일선치료NSCLC료효교호,내수성량호,가명현개선증상,제고환자생활질량.
Objective To evaluate the clinical efficacy and toxicity of gefitinib in the first line treatment of patients with advanced non-small-cell lung cancer (NSCLC).Methods Fifty-eight NSCLC patients were treated with gefitinib 250 mg orally taken once daily until disease progression or the occurrence of intolerablet toxicity.After two months' treatment,the clinical efficacy and toxicity were analyzied.Synchronously,the EGFR mutation status of tumor samples was detected.Results Among these 58 patients,there were 2 cases with CR(3.4％ ),16 cases with PR(27.6％ ),24 cases with SD(41.4％ ),16cases with PD(36.5％ ).The disease control rate was 72.4％.The clinical benefit rate was significantly correlated with gender,pathologic type,smoking history and the status of EGFR,but not with clinical stage.The mutation rates of EGFR was 51.7％ (30/58).Conclusions In the first line treatment of patients with advanced NSCLC,gefitinib is effective and safe which can relieve symptom and improve the quality of the life.